机构：[1]Fudan Univ, Huashan Hosp, Shanghai, Peoples R China[2]Shandong First Med Univ, Jinan, Peoples R China[3]Cent South Univ, Xiangya Hosp, Changsha, Peoples R China[4]Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China首都医科大学宣武医院[5]Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China[6]Beijing Hosp, Beijing, Peoples R China[7]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[8]Harbour BioMed, Shanghai, Peoples R China
第一作者机构：[1]Fudan Univ, Huashan Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Yan C.,Duan R.,Yang H.,et al.A double-blinded, randomized, placebo-controlled phase II study of FcRn antagonist batoclimab in Chinese generalized myasthenia gravis patients[J].NEUROMUSCULAR DISORDERS.2022,32:S82-S82.doi:10.1016/j.nmd.2022.07.169.
APA：
Yan, C.,Duan, R.,Yang, H.,Li, H.,Zou, Z....&Zhao, C..(2022).A double-blinded, randomized, placebo-controlled phase II study of FcRn antagonist batoclimab in Chinese generalized myasthenia gravis patients.NEUROMUSCULAR DISORDERS,32,
MLA：
Yan, C.,et al."A double-blinded, randomized, placebo-controlled phase II study of FcRn antagonist batoclimab in Chinese generalized myasthenia gravis patients".NEUROMUSCULAR DISORDERS 32.(2022):S82-S82
